Vireo Growth (VREOF) Profit After Tax Growth (3y) (2023 - 2026)
Vireo Growth (VREOF) Profit After Tax Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.21 Bn | 39.55 Bn | 2.15 Bn | 14.01% |
| 3 | Zoetis | 31.48 Bn | 29.80 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 2.89% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.49 Bn | 15.10 Bn | 935.80 Mn | 15.37% |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Vireo Growth | 489.19 Mn | 346.89 Mn | 95.30 Mn | 76.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.16% |
| Dec 31, 2025 | -15.32% |
| Sep 30, 2025 | -46.15% |
| Jun 30, 2025 | -34.17% |
| Mar 31, 2025 | 23.58% |
| Dec 31, 2024 | -6.68% |
| Sep 30, 2024 | 10.49% |
| Jun 30, 2024 | 54.32% |
| Mar 31, 2024 | 0.81% |
| Dec 31, 2023 | -26.46% |
| Sep 30, 2023 | -55.66% |
| Jun 30, 2023 | 23.10% |
| Mar 31, 2023 | -3.81% |